Skip to content
★ Sign in to follow
TP

Tianda Pharmaceuticals Ltd. Stock: price and insider trades · Hong Kong

HK·Mcap HK$221.5M

No insider purchase over the last 90 days. The latest, by Fang Wen Quan, was filed 03 Jan 2023.

Tianda Pharmaceuticals Ltd.: what insiders have been doing

Tianda Pharmaceuticals Ltd. is a listed company. Filings by its managers are published through HKEX. Nothing new has been filed by managers of Tianda Pharmaceuticals Ltd. in twelve months, the latest record being from 3 January 2023.

Looking back to 2022, when coverage begins, insiders filed 20 purchases and no sales.

Elsewhere in the same market, our signals recently picked up insider purchases at Sun Hung Kai Properties Ltd. and Xinyi Glass Holdings Ltd. Source: insider filings from HKEX. Past trades are no guide to future returns.

Insider Decl.
20
Thresholds
n/a
Buy Volume
€921,772
20 ops. · all time
Sell Volume
n/a
n/a

Since the insiders bought

  • Filed 03 Jan 2023 · 1405 days ago · €323k
    -44.7%
    Entry HK$0.41 · Close at T+365 HK$0.22

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 23,775 of 26,897 companies
23.4
score / 100
Value
18
Quality
29
FCF yld-3.0%
Earn yld-32%
EV/EBITDA·
ROE-15%
Gross mgn41%
Net mgn-22%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$0.10
Analyst consensus
·
Income statement
RevenueHK$322.9M
Gross profitHK$133.3M41% margin
EBITDA-HK$27.1M-8% margin
Net income-HK$70M-19.7% margin
Valuation
P/Book0.5x
Beta-0.02
Balance sheet & cash
Market capHK$221.5M
Total debtHK$132.7M
Free Cash Flow-HK$6.6M
Debt / Equity33%
Profitability & ownership
ROE-14.9%
ROA-4.1%
% insiders79.4%
% institutions0.0%
Last declaration on 3 January 2023
Declarations20 total
  • ▲
    DirectorExecutives
    3M HKD15HKEX
    6,808,000 shares@ HK$0.394435.0% of flowShareXHKGHKEX:DA20230103E00257
    Canonical exit: 30 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    323,652 HKD11HKEX
    840,000 shares@ HK$0.38534.2% of flowShareXHKGHKEX:DA20221228E00200
    Canonical exit: 23 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    792,573 HKD12HKEX
    2,130,000 shares@ HK$0.372110.4% of flowShareXHKGHKEX:DA20221228E00198
    Canonical exit: 22 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    233,344 HKD11HKEX
    640,000 shares@ HK$0.36463.1% of flowShareXHKGHKEX:DA20221223E00060
    Canonical exit: 21 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    279,202 HKD11HKEX
    770,000 shares@ HK$0.36263.7% of flowShareXHKGHKEX:DA20221223E00059
    Canonical exit: 20 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    448,476 HKD12HKEX
    1,330,000 shares@ HK$0.33725.9% of flowShareXHKGHKEX:DA20221221E00341
    Canonical exit: 19 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    516,909 HKD12HKEX
    1,590,000 shares@ HK$0.32516.8% of flowShareXHKGHKEX:DA20221220E00043
    Canonical exit: 16 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    474,936 HKD12HKEX
    1,542,000 shares@ HK$0.3086.2% of flowShareXHKGHKEX:DA20221219E00004
    Canonical exit: 14 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    636,165 HKD12HKEX
    2,010,000 shares@ HK$0.31658.3% of flowShareXHKGHKEX:DA20221219E00005
    Canonical exit: 15 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    175,332 HKD11HKEX
    570,000 shares@ HK$0.30762.3% of flowShareXHKGHKEX:DA20221215E00022
    Canonical exit: 13 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    235,981 HKD11HKEX
    838,000 shares@ HK$0.28163.1% of flowShareXHKGHKEX:DA20221213E00062
    Canonical exit: 12 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    273,768 HKD11HKEX
    1,220,000 shares@ HK$0.22443.6% of flowShareXHKGHKEX:DA20221212E00235
    Canonical exit: 9 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    20,400 HKD11HKEX
    102,000 shares@ HK$0.200.3% of flowShareXHKGHKEX:DA20221209E00362
    Canonical exit: 8 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    82,029 HKD11HKEX
    412,000 shares@ HK$0.19911.1% of flowShareXHKGHKEX:DA20221209E00078
    Canonical exit: 7 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    52,360 HKD11HKEX
    280,000 shares@ HK$0.1870.7% of flowShareXHKGHKEX:DA20221207E00308
    Canonical exit: 6 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    34,254 HKD11HKEX
    198,000 shares@ HK$0.1730.5% of flowShareXHKGHKEX:DA20221207E00307
    Canonical exit: 5 Mar 2023 (T+90)
  • ▲
    DirectorExecutives
    106,980 HKD11HKEX
    600,000 shares@ HK$0.17831.5% of flowShareXHKGHKEX:DA20221025E00242
    Canonical exit: 22 Jan 2023 (T+90)
  • ▲
    DirectorExecutives
    53,545 HKD11HKEX
    302,000 shares@ HK$0.17730.8% of flowShareXHKGHKEX:DA20221025E00241
    Canonical exit: 19 Jan 2023 (T+90)
  • ▲
    DirectorExecutives
    129,256 HKD11HKEX
    742,000 shares@ HK$0.17421.8% of flowShareXHKGHKEX:DA20221021E00231
    Canonical exit: 18 Jan 2023 (T+90)
  • ▲
    DirectorExecutives
    49,764 HKD11HKEX
    286,000 shares@ HK$0.1740.7% of flowShareXHKGHKEX:DA20221021E00230
    Canonical exit: 17 Jan 2023 (T+90)

20 of 20 declarations

About Tianda Pharmaceuticals Ltd.

Tianda Pharmaceuticals Ltd. is a Hong Kong Stock Exchange-listed pharmaceutical company focused on the development and commercialization of pharmaceutical products. It specializes in treatments for various diseases and medical conditions.

Recent ranked signals on the same market

Purchases our model currently ranks for the recommendations list.

All recommendations